Racial Disparities in Early Lung Cancer Treatment, Outcomes Persist

Video

This video examines racial disparities in treatment and survival outcomes among stage I non–small-cell lung cancer lung cancer patients.

In this video, Andrew Farach, MD, of Houston Methodist Hospital, discusses results of a Surveillance, Epidemiology, and End Results (SEER) database study that examined the outcomes of over 60,000 patients diagnosed with stage I non–small-cell lung cancer (NSCLC) from 2004 to 2012.

The study found that treatment with surgery varied by race of the patient (72%, Asian/Pacific Islander; 67%, Caucasian; 58%, American Indian; and 56%, African-American; P < .05). Survival outcomes at a median follow-up of 23 months varied as well (76%, Asian/Pacific Islander; 70%, Caucasians; 65%, African Americans; and 60% American Indians; P < .05).

Farach presented the results (abstract 9) at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

Russ Conroy
April 3rd 2025
Article

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.

Tobacco Control Helps Avert Millions of Lung Cancer Deaths

Russ Conroy
March 27th 2025
Article

A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

Tim Cortese
February 5th 2025
Article

The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.

Lung cancer

Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer

Silas Inman
September 7th 2024
Article

Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.